Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation

A Magnetic Resonance Spectroscopy Study of Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00801567

Enrollment

Registered

2008-12-03

Start date

2010-06-30

Completion date

2010-06-30

Last updated

2012-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Healthy Controls, Schizophrenia

Keywords

Bipolar disorder, Schizophrenia, Healthy volunteer, Brain imaging, Photic stimulation

Brief summary

This study aims to gather additional information to support the theory that bipolar disorder is due to cellular (mitochondrial) dysfunction. To test this theory adults with bipolar disorder who are not currently symptomatic will receive a one-time brain scan (magnetic resonance spectroscopy \[MRS\] scan) with light stimulation. To test whether any MRS findings are specific to bipolar disorder, healthy controls and adults with schizophrenia will also be included in this study.

Detailed description

This study will include males and females between the ages of 18 and 55 years. Participants will include adults with stable bipolar disorder or schizophrenia as well as healthy controls. The study involves a one-time visit that includes a clinical evaluation, laboratory tests, and a magnetic resonance scan that will last approximately 90 minutes. The procedures can also be separated into two study visits, if necessary.

Interventions

DEVICEMagnetic resonance spectroscopy (MRS)

90-minute magnetic resonance scan.

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Male of female * 18-55 years * Bipolar, currently euthymic OR schizophrenia, stable, OR healthy control with no history of psychiatric illness * On stable medication with no changes in the two weeks prior to enrollment

Exclusion criteria

* History of substance abuse or dependence within 3 months of enrollment * Positive urine drug screen * Significant medical or neurological illness * Pregnancy * Any contraindication to magnetic resonance scanning, including claustrophobia

Design outcomes

Primary

Measure	Time frame
Change in brain levels of phosphocreatine (PCr), beta-nucleoside triphosphate (B-NTP), and intracellular pH (pHi).	42 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026